Detalles de la búsqueda
1.
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Breast Cancer Res Treat
; 203(3): 497-509, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37938495
2.
Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer.
Ann Surg Oncol
; 30(12): 7026-7035, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37490162
3.
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Br J Cancer
; 127(10): 1799-1807, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36050448
4.
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).
Oncologist
; 2022 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35445723
5.
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Breast Cancer Res Treat
; 185(1): 107-116, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32951084
6.
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
J Natl Compr Canc Netw
; 19(2): 181-189, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33401235
7.
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
Br J Cancer
; 122(10): 1453-1460, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32203207
8.
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Breast Cancer Res Treat
; 182(3): 613-622, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32504284
9.
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Cancer
; 125(2): 307-316, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335191
10.
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Breast Cancer Res Treat
; 177(1): 103-114, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31134488
11.
ASO Visual Abstract: Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node-Negative T1 Triple-Negative Breast Cancer.
Ann Surg Oncol
; 30(12): 7143, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37574519
12.
Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
Breast Cancer Res
; 19(1): 130, 2017 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29212525
13.
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a subanalysis of the ALTTO trial (BIG 206; NCCTG (Alliance) N063D).
Breast Cancer Res Treat
; 191(1): 225, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34625860
14.
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat
; 165(2): 329-341, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28612225
15.
Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
Breast Cancer Res
; 23(1): 41, 2021 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33766079
16.
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 16(15): 1556-1568, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26482278
17.
Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
Breast Cancer Res Treat
; 153(2): 435-43, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26296701
18.
Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
Cancer
; 119(13): 2447-54, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23585192
19.
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Cancer
; 119(15): 2675-82, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23744760
20.
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Breast Cancer Res Treat
; 138(2): 427-35, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23479422